Modern Alternatives to Enzymatic Capping of mRNA

For companies looking to bring mRNA therapeutics and vaccines to market, TriLink’s proprietary GMP-grade CleanCap® reagents offer an immediate solution for swiftly scaling from clinical to commercial. CleanCap technology is the fastest and easiest way to produce a 5’ Cap1 mRNA with 95% efficiency. GMP CleanCap reagents are a modern alternative to enzymatic capping and are ready to accelerate your mRNA therapeutic development. In this podcast, we will discuss how TriLink discovered this mRNA capping method and how they made it scalable to support global vaccine supply, as a key raw material for over 3 billion vaccines doses against COVID-19.